WallStSmart

Addus HomeCare Corporation (ADUS)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3877% more annual revenue ($56.58B vs $1.42B). NVS leads profitability with a 23.9% profit margin vs 6.7%. ADUS appears more attractively valued with a PEG of 0.96. ADUS earns a higher WallStSmart Score of 70/100 (B).

ADUS

Strong Buy

70

out of 100

Grade: B

Growth: 8.7Profit: 5.5Value: 7.3Quality: 6.3
Piotroski: 2/9Altman Z: 3.11

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ADUSUndervalued (+25.9%)

Margin of Safety

+25.9%

Fair Value

$152.11

Current Price

$96.89

$55.22 discount

UndervaluedFair: $152.11Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADUS5 strengths · Avg: 8.8/10
EPS GrowthGrowth
52.1%10/10

Earnings expanding 52.1% YoY

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.968/10

Growing faster than its price suggests

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
25.6%8/10

Revenue surging 25.6% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

ADUS3 concerns · Avg: 3.0/10
Market CapQuality
$1.81B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ADUS

The strongest argument for ADUS centers on EPS Growth, Altman Z-Score, PEG Ratio. Revenue growth of 25.6% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : ADUS

The primary concerns for ADUS are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

ADUS profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

ADUS carries more volatility with a beta of 0.96 — expect wider price swings.

ADUS is growing revenue faster at 25.6% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

ADUS scores higher overall (70/100 vs 51/100) and 25.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Addus HomeCare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?